Genetic Risk Factors in Parkinson's Disease

Parkinson’s disease is a progressive neurodegenerative disorder whose heritable component spans rare, highly penetrant mutations and common variants with modest effects. Monogenic forms due to mutations in genes such as SNCA, LRRK2 and GBA account for a minority of cases but have illuminated core pathways including α-synuclein aggregation and lysosomal dysfunction. Genome-wide association studies have identified over a hundred susceptibility loci that collectively explain a substantial fraction of heritability, while polygenic risk scores capture the cumulative burden of numerous small-effect alleles. Ethnic-specific risk signals and rare truncating variants further underscore the diversity of genetic architecture across populations. Convergent evidence implicates interconnected mechanisms—lysosomal clearance, mitochondrial bioenergetics, synaptic maintenance and immune modulation—offering a framework for precision medicine and targeted therapeutic development.

Research from Nature Portfolio

Recent analyses of an African ancestry-specific noncoding variant in the GBA1 gene have demonstrated that disruption of a key intronic branchpoint leads to retention of intron 8, resulting in reduced functional transcript levels and diminished glucocerebrosidase activity in a dose-dependent manner. This work extends the pathogenic spectrum of GBA1 beyond coding mutations and highlights RNA-based mechanisms as critical contributors to disease risk in underrepresented populations.

A transcriptome-wide association study applied to large neuronal and immune cell expression datasets has prioritised dozens of candidate genes whose splicing or expression levels are significantly associated with Parkinson’s risk. Notably, variation in exon 3 splicing of the MAPT gene and dysregulation of lysosomal and innate immune pathways have emerged as central drivers of susceptibility, establishing new mechanistic targets for biomarker and therapeutic research.

Genetic Risk Factors in Parkinson's Disease publication trend

The graph below shows the total number of articles in genetic risk factors in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Genome-wide association study (GWAS): An approach that scans common genetic variants across the genome to identify loci associated with disease risk.

Transcriptome-wide association study (TWAS): A method linking predicted gene expression or splicing patterns to disease susceptibility using large transcriptomic datasets.

Polygenic risk score (PRS): A numerical value that aggregates the effects of many genetic variants to estimate an individual’s inherited predisposition to a disease.

Induced pluripotent stem cell (iPSC): A somatic cell reprogrammed to an embryonic-like state, capable of differentiating into various cell types for disease modelling.

Intron branchpoint: A conserved sequence within an intron critical for correct RNA splicing; its disruption can lead to aberrant transcript retention.

References

1. The Foundational Data Initiative for Parkinson Disease: Enabling efficient translation from genetic maps to mechanism. Cell Genomics (2023).
2. African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1. Nature Structural & Molecular Biology (2024).
3. Genome-wide association study using whole-genome sequencing identifies risk loci for Parkinson’s disease in Chinese population. npj Parkinson's Disease (2023).
4. Prioritizing Parkinson’s disease genes using population-scale transcriptomic data. Nature Communications (2019).
5. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset. npj Parkinson's Disease (2019).
6. Genetics and Pathogenesis of Parkinson's Syndrome. Annual Review of Pathology Mechanisms of Disease (2022).